Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tebapivat
- Development stage
- Phase 2
- Lead developer
- Agios Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tebapivat is an investigational, oral small molecule that acts as a potent activator of pyruvate kinase (PK), including the red blood cell-specific isoform (PKR) and M2 isoform (PKM2). By activating PK, tebapivat enhances glycolytic pathway activity in erythrocytes, leading to increased adenosine triphosphate (ATP) production and improved red blood cell energy metabolism. This mechanism is intended to address anemia by improving red blood cell survival and function. Tebapivat is being developed primarily for the treatment of anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) and sickle cell disease. It is currently under investigation in phase 2 clinical trials for these indications[6][7][9][10].
- Other names
- tebapivatAG-946AG946AG 946
02
Targets
PK (Pyruvate kinase)
Beyond the preview
Go deeper on tebapivat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tebapivat.